Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV003077778 | SCV003462827 | benign | Hypokalemic periodic paralysis, type 1; Malignant hyperthermia, susceptibility to, 5 | 2022-06-28 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003077777 | SCV003574456 | uncertain significance | Inborn genetic diseases | 2021-08-12 | criteria provided, single submitter | clinical testing | The c.2350C>G (p.P784A) alteration is located in exon 17 (coding exon 17) of the CACNA1S gene. This alteration results from a C to G substitution at nucleotide position 2350, causing the proline (P) at amino acid position 784 to be replaced by an alanine (A). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
All of Us Research Program, |
RCV004009367 | SCV004825395 | uncertain significance | Malignant hyperthermia, susceptibility to, 5 | 2023-11-20 | criteria provided, single submitter | clinical testing | This missense variant replaces proline with alanine at codon 784 of the CACNA1S protein. Computational prediction is inconclusive regarding the impact of this variant on protein structure and function (internally defined REVEL score threshold 0.5 < inconclusive < 0.7, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has not been reported in individuals affected with CACNA1S-related disorders in the literature. This variant has been identified in 4/282640 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. |